2017 Speakers




KEYNOTE







Lynda Chin

Chief Innovation Officer & Associate Vice Chancellor

The University of Texas System




Lynda Chin, M.D. is currently the Chief Innovation Officer and associate vice chancellor for health affairs, director of the Institute for 

Health Transformation at the University of Texas System, focusing on addressing the rising chronic disease burden that is threatening 

the health and productivity of Americans and the solvency of its healthcare system through innovative technology and business 

solutions and cross-enterprise collaborations. Dr. Chin is a member of the National Academy of Medicine as well as a member of The 

Association of American Physicians.

Dr. Chin graduated with a M.D. degree from Albert Einstein College of Medicine and is a board-certified dermatologist. She conducted 

her clinical and scientific training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine, where she 

completed in parallel her residency training in the hospital and postdoctoral fellowship in the laboratory.  In addition to opening the 

first Chinese-speaking dermatology specialty practice in NY Chinatown, Dr. Chin conducted her academic research at Dana-Farber 

Cancer Institute where she was a professor of dermatology at Harvard Medical School and a senior associate member of the Broad 

Institute of MIT and Harvard. Her research program spans the fields of transcription, telomere biology, cancer genomics, and personalized 

cancer medicine. Dr. Chin held multiple leadership roles in The Cancer Genome Atlas. She is a member of the Scientific Steering Committee 

of the International Cancer Genome Consortium.  Dr. Chin joined MD Anderson Cancer Center from 2011-2015 as the founding chair for 

the Department of Genomic Medicine, with a mission to bring to bear on cancer not only the transformative potential of genomics, but also 

of data, technologies and innovative strategies. 

Throughout her career, Dr. Chin has championed a model of integration, collaboration and cooperation between the research and clinical 

care enterprises, as well as between public and private sectors. She was the Scientific Director of the Belfer Institute for Applied Cancer 

Science at Dana-Farber Cancer Institute and subsequently the Institute for Applied Cancer Science at MD Anderson, an organization 

designed to bring together the best attributes of academia and industry in a new organizational construct to rapidly translate cancer 

genomics knowledge into effective therapeutic endpoints.  At MD Anderson, she conceptualized and led the development of MD Anderson 

Oncology Expert Advisor© in partnership with IBM Watson, an example of a cognitive expert system for democratization of clinical expertise 

for evidence-based care. Together with her colleague Dr. Andrew Futreal, she launched the effort to integrate the research and clinical 

care enterprises at MD Anderson by establishing the Translational Research Accelerator, a big data platform linking longitudinally research 

and clinical data on patients.

In her current endeavor, Dr. Chin has architected a digital health platform built collaboratively with AT&T, IBM and PwC to enable secure 

and compliant sharing and uses of contextualized patient health profiles synthesized from not only EHR data, but also real-world clinical data, 

patient-generated health data and other data sources. With such data connectivity, she has convened an ecosystem of technology, service, 

retail and healthcare stakeholders in both public and private sectors to collaborate in tackling the challenges of diabetes and chronic disease 

in an underserved community in South Texas.












Daryl Pritchard

Senior Vice President, Science Policy

Personalized Medicine Coalition




Daryl Pritchard, Ph.D., is the Senior Vice President of Science Policy at the Personalized Medicine Coalition (PMC), where he 

leads PMC’sefforts to increase awareness and understanding of personalized medicine;identify and address barriers to the 

adoption of personalized medicine into the healthcare system;and develop and promote appropriate clinical, healthcare 

infrastructure, regulatory, and payment policies.

Before coming to PMC, Dr. Pritchard served as the Director of Policy Research at the National Pharmaceutical Council (NPC).  

Prior to joining NPC, he served as the Director of Research Programs Advocacy and Personalized Medicine at the 

Biotechnology Industry Organization (BIO).

Dr. Pritchard received his Ph.D. and master’s degree in genetics from the George Washington University, and completed a 

post-doctoral research fellowship at the Children’s National Medical Center. He was awarded the first American Society of 

Human Genetics (ASHG)/National Human Genome Research Institute (NHGRI) Fellowship in Genetics and Public Policy, where 

he worked as a health legislative assistant in the House of Representatives.










Gene Sequencing & Big Data Forum







Zhi Xie

Director of Biomedical Big Data Center

SUN YAT-SEN UNIVERSITY












Zhiyuan Hu

Director

National Center for Nanscience and Technology












Anjia Han

Director of Department of Pathology

The First Affiliated Hospital, Sun Yat-sen University










Liquid Biopsy Technology Forum







Jianyong Shao

Director of Molecular Diagnostics Section of Cancer Center, 

SUN YAT-SEN UNIVERSITY












Sheng Li

Director of Shandong Institute of Drugs, Surgeon, Shandong Tumor Hospital

Shandong Institute of Drugs&Shandong Tumor Hospital












Lei Zheng

Deputy Director of Laboratory

Southern Medical University Affiliated Southern Hospital












Hao Zhang

Vice Dean, Director 

Cancer Research Center Shantou University Medical College Affiliated Cancer Hospital












Jiatao Lou

Professor of Pathology

School of Basic Medical Sciences, Fudan University













Deming Gou

Professor of College of Life Science and Oceanography

Shenzhen University




Dr. Deming Gou, a distinguished professor at the College of Life Sciences and Oceanography in Shenzhen University, used to be 

Postdoctor and associate professor in Wuhan University, the research associate professor in Oklahoma State University (OSU) and 

assistant professor in the University of Illinois at Chicago (UIC). Dr. Gou is a member of the American heart association, the American 

physical society and the Chinese physical society; the editor of Scientific Reports. Dr.Gou : (1) The role of ncRNAs in the development 

of pulmonary arterial hypertension (PAH); (2) Identification of circulating miRNA  biomarker and its application in the early diagnosis of  

lung cancer. He has developed the most sensitive method (S-PolyTplus) for miRNA detection. Within recent five years, Dr.Gou`s team 

has published 39 articles in high quality SCI journals, such as American Journal of Respiratory and Critical Care Medicine, Cell Death 

and Differentiation,JBC, Am J Respir Cell Mol Biol. 












Hongli Yan

Deputy director of Experimental Diagnosis Department, 

Second Military Medical University Affiliated Changhai Hospital










Oncology Drug Precision Development Forum







Elizabeth Mansfield

Head,Regulatory Strategy at GRAIL, Former Director of Personalized Medicine, FDA

GRAIL




Elizabeth Mansfield is the Head of Regulatory Strategy at GRAIL. Prior to GRAIL, Liz was Deputy Office Director for Personalized 

Medicine and Director of the Personalized Medicine Staff in the Office of In Vitro Diagnostic Devices (OIVD) in the Center for 

Devices at the FDA, where she developed a program to address companion and novel diagnostic devices. She also previously 

served as a Senior Policy Analyst in OIVD, managing policy and scientific issues, and served in other positions at the FDA 

including Scientific Reviewer and Genetics Expert. Previously at Affymetrix, Liz was the Director of Regulatory Affairs (2004-2006). 

She holds a PhD from Johns Hopkins University and completed further postdoctoral training at the National Cancer Institute (NCI) 

and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS).












Zhaoqian Liu

Vice President, Central South University Affiliated Xiangya Hospital












Ye Hua

Senior Vice President, Head, Clinical Development & Regulatory Affairs

Hutchison MediPharma




Ye Hua, MD, MPH is Senior VP, Head of Clinical Development and Regulatory Affairs at Hutchison MediPharm, a novel drug R&D

company focusing on drug discovery and development for innovative therapies in oncology and autoimmune diseases.Managing 

the clinical and regulatory organization, Dr. Hua is responsible foradvancingclinical development pipelineand registering new drugs 

in China and ex-China. Under his leadership, the clinical development programs have grown from 5 small molecules in 7 Phase 1 

oncology clinical trials to 8 small molecules in over 30 Phase 1-3 clinical trials in oncology and immunology in China, Australia, and 

USA. Most recently, Dr. Hua led fruquintinib NDA submission inmCRCindication via MAH pilot policy. 

Native from Shanghai, Dr. Hua graduated from Fudan University Shanghai Medical College in 1992. He worked as a cancer 

epidemiologist at Shanghai Cancer Institute between 1992 and 1996, and then went to McGill University in Montreal Canada to 

pursue a Master Degree in cancer epidemiology. 

Dr. Hua is a senior clinical research physician who has over seventeen years’ global clinical development and new drug registration 

experience in the pharmaceutical industry. Hestarted his career in the pharmaceutical industry as a biostatistician at Pharmacia & 

Upjohn in 1999, and worked through the rank in biostatistics. His most significant achievement being the statistical team leader for the 

pivotal Phase 3 RA registration trial of Humirathat won regulatory approval in the US and EU. 

Often contributed to clinical programs beyond his role in statistics, Dr. Hua was well recognized and greatly appreciated by cross-functional 

development teams. In 2004,one year after joining Novartis, Dr. Huasuccessfully switched career track back to clinical. Beinga medical 

monitor, he led a number of global Phase II/III registration trials in osteoarthritis, osteoporosis, infectious diseases,oncology and hematology 

disease areas. As clinical project leader, Dr. Hua contributed to the regulatory approval and life-cycle management for Reclast/Aclasta, 

Prexige, Zometa, Femara, Proleukin and Cardioxane in the US and EU. His last job in the US was Senior Director,Global Clinical Development, 

Celgene Corporation where he led several global clinical teams for Revlimid and PomalystNDA/sNDA in multiple myeloma indication, and 

eventually obtained regulatory approval in the US and EU. In addition, he led clinical subteam executed registration trials for Revlimid and 

Pomalyst in China, and successfully obtained Revlimid regulatory approval in multiple myeloma indication.












Bin Ye

Vice President, Clinical Biomarker and Drug Development, Precision Medicine

Beijing Shenogen Biomedical Co.












Hua Chang

Senior director, Novartis(United States)




Dr. Hua Gong has over 18 years of broad and progressive management and leadership roles in both R&D and clinical expertise in the 

development of biomarker and diagnostic products. She currently serves as the Sr. Director of Clinical Trial Testing at Navigator 

Biopharma in Novartis (Formerly Genoptix). She overseesa team of 41 associates including PhDs and supports over 70 oncology trials 

by selecting patients for oncology clinical trials based on patient’s biomarkerprofiling. Before she joined Genoptix in 2013, she was the 

Executive Director and head of Medical Device and Diagnostics. She headed up the IVD group and provided clinical development and 

regulatory submission services for diagnostics companies in US and EU. She managed the companion diagnostics service for 

pharmaceutical companies to stratify patients in their drug development. Prior to joining Premier Research, Dr. Gong was the Associate 

Director, Medical Diagnostics at Prometheus Therapeutics & Diagnostics where she was responsible for leading the development of 

companion diagnostics for pharmaceutical companies, overseeing multiple clinical studies to validate their oncology platform as well as 

contributed to their CEER HER2 510K submission. Additionally, she worked at Pfizer for 10 years in a variety of positions of increasing 

responsibility. In her last position at Pfizer, Dr. Gong served as Principal Scientist, Oncology Exploratory Biology where she managed a 

multi-disciplinary team including intro/vivo biology, PDM, drug safety and biomarker research groups. Dr. Gong received a Bachelor in 

Medicinedegree in Ai Hui Medical University, a Master degree from the Sun Yat-Sun University of Medical Sciences in Guangzhou, and a 

doctorate in Cancer Biology from Wayne State University in US. 












Jingfeng Xu

Director of Clinical Pharmacology

Army General Hospital












Li-Wu Fu

Director of Experimental Research Department of Cancer Center, 

SUN YAT-SEN UNIVERSITY












Hubing Shi

Professor of State Key Laboratory of biological therapy

West China Hospital of Sichuan University




Hubing Shi obtained his Ph.D. degree from Dr. Yongzhang Luo’s laboratory at Tsinghua University in 2007., His research interests in 

graduated school focused on unraveling the molecular mechanism of tumor angiogenesis and microenvironment regulation. He reported 

that nucleolin is a receptor for endostatin, and illuminated the mechanism of how endostatin dynamically adjusts tumor neovascular balance 

through nucleolin.

Dr. Shi continued his cancer biology research in Drs. Roger S. Lo and Antoni Ribas’ laboratories at University of California, Los Angeles 

(UCLA) as a postdoctoral fellow since 2009. By taking advantage of high-throughput sequencing technologies, he, along with his colleagues, 

systematically illuminated the molecular mechanism of acquired BRAF inhibitor resistance in advanced metastatic melanoma, including 

1) NRAS mutation, 2) RTK upregulation, 3) BRAF gene amplification, 4) BRAF alternative splicing (collaborated with Dr. David Solit group), 

5) mutations in PI3K/AKT pathway, 6) cMET/YAP1/LEF1 activation, and 7) MEK1Mut/BRAFAmp in BRAFi/MEKi double drug resistance.

As an independent investigator, he continues his research on the fundamental molecular mechanisms involved in tumor acquired drug 

resistance, especially, in term of tumor microenvironment. 












Chuxia Deng

Dean

School of health sciences, University of Macau












Rongcheng Luo

Dean

TCM-Integrated Cancer Center of Southern Medical University